Citius Oncology, Inc.(CTOR) - 2024 Q3 - Quarterly Results

§ A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Exhibit 99.1 CRANFORD, N.J., December 27, 2024 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for ...